BioPharma Credit PLC




Closed End Funds

Market Closed - London S.E. 11:35:04 2024-06-21 am EDT 5-day change 1st Jan Change
0.846 USD -0.47% Intraday chart for BioPharma Credit PLC +1.44% +0.71%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
BioPharma Credit Enters $400 Million Loan Agreement with Novocure Luxembourg MT
BioPharma Credit agrees USD400 million loan for oncology firm Novacure AN
BioPharma Credit, Unit to Loan up to $100 Million Each to US-based Tarsus Pharmaceuticals MT
BioPharma Credit to loan USD100 million to Tarsus Pharmaceuticals AN
BioPharma Credit PLC Reports Earnings Results for the Full Year Ended December 31, 2023 CI
BioPharma Credit Board, Investment Manager Propose Changes to Discount Control Mechanism MT
BioPharma Credit Logs Lower FY23 Net Income Return on Ordinary Activities MT
Tranche Update on BioPharma Credit PLC's Equity Buyback Plan announced on May 31, 2023. CI
BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase AN
Biopharma Credit Secures $51 Million Loan Repayment from US Biotech ImmunoGen MT
Jefferies Downgrades BioPharma Credit to Hold from Buy MT
Jefferies cuts BioPharma Credit to 'hold' AN
Barratt takes over Redrow in GBP2.5 billion deal AN
BioPharma Credit to receive partial prepayment of loan AN
BioPharma Credit to fund LumiraDx ahead of acquisition by Roche AN
BioPharma Credit notes loan agreement amendment by LumiraDx AN
BioPharma Credit notes AbbVie takeover of investee ImmunoGen AN
BioPharma Credit says liquidity covenant in loan deal waived AN
BioPharma Credit PLC Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Anglo Asian to restart Gedabek operations on approval AN
BioPharma Credit notes liquidity amendments to LumiraDX loan deal AN
Jefferies Upgrades BioPharma Credit to Buy from Underperform MT
Jefferies likes Energean; JPMorgan raises IDS AN
BioPharma Credit PLC(LSE:BPCR) added to S&P Global BMI Index CI
Byotrol loss widens, Surface Transforms sales grow AN
Chart BioPharma Credit PLC
More charts
BioPharma Credit PLC is a United Kingdom-based specialist debt investor to the life sciences industry. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. It seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products. The Company may also invest in equity issued by a life sciences company, acquired directly from the life sciences company or in the secondary market. It will seek to create a diversified portfolio of investments by investing across a range of different forms of debt assets issued by a variety of borrowers. It has two wholly owned subsidiaries: BPCR Limited Partnership and BPCR GP Limited. The Company holds a majority of its investments through its financing subsidiary, BPCR Limited Partnership. Its investment manager is Pharmakon Advisors, LP.
More about the company
Mean consensus
Number of Analysts
Last Close Price
Average target price

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. BPCP Stock
  4. News BioPharma Credit PLC
  5. BioPharma Credit Enters $400 Million Loan Agreement with Novocure Luxembourg